DAY ONE BIOPHARMACEUTICALS I (DAWN) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:DAWN • US23954D1090

11.465 USD
-0.04 (-0.3%)
Last: Feb 3, 2026, 09:46 AM
Fundamental Rating

4

DAWN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. While DAWN has a great health rating, there are worries on its profitability. While showing a medium growth rate, DAWN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • DAWN had negative earnings in the past year.
  • In the past year DAWN has reported a negative cash flow from operations.
  • In the past 5 years DAWN always reported negative net income.
  • In the past 5 years DAWN always reported negative operating cash flow.
DAWN Yearly Net Income VS EBIT VS OCF VS FCFDAWN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • With a decent Return On Assets value of -29.54%, DAWN is doing good in the industry, outperforming 67.37% of the companies in the same industry.
  • With a decent Return On Equity value of -33.66%, DAWN is doing good in the industry, outperforming 73.47% of the companies in the same industry.
Industry RankSector Rank
ROA -29.54%
ROE -33.66%
ROIC N/A
ROA(3y)-35.78%
ROA(5y)-50.98%
ROE(3y)-38.78%
ROE(5y)-56.84%
ROIC(3y)N/A
ROIC(5y)N/A
DAWN Yearly ROA, ROE, ROICDAWN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • DAWN's Gross Margin of 89.44% is amongst the best of the industry. DAWN outperforms 91.98% of its industry peers.
  • DAWN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DAWN Yearly Profit, Operating, Gross MarginsDAWN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

  • DAWN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for DAWN has been increased compared to 1 year ago.
  • DAWN has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for DAWN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DAWN Yearly Shares OutstandingDAWN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
DAWN Yearly Total Debt VS Total AssetsDAWN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • DAWN has an Altman-Z score of 9.73. This indicates that DAWN is financially healthy and has little risk of bankruptcy at the moment.
  • DAWN has a Altman-Z score of 9.73. This is amongst the best in the industry. DAWN outperforms 81.49% of its industry peers.
  • DAWN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.73
ROIC/WACCN/A
WACC8.9%
DAWN Yearly LT Debt VS Equity VS FCFDAWN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • DAWN has a Current Ratio of 8.68. This indicates that DAWN is financially healthy and has no problem in meeting its short term obligations.
  • DAWN has a Current ratio of 8.68. This is in the better half of the industry: DAWN outperforms 76.91% of its industry peers.
  • DAWN has a Quick Ratio of 8.55. This indicates that DAWN is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of DAWN (8.55) is better than 76.53% of its industry peers.
Industry RankSector Rank
Current Ratio 8.68
Quick Ratio 8.55
DAWN Yearly Current Assets VS Current LiabilitesDAWN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 17.42% over the past year.
  • DAWN shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.11%.
EPS 1Y (TTM)17.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.65%
Revenue 1Y (TTM)31.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%98.28%

3.2 Future

  • DAWN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.77% yearly.
  • Based on estimates for the next years, DAWN will show a very strong growth in Revenue. The Revenue will grow by 36.57% on average per year.
EPS Next Y42.41%
EPS Next 2Y28.45%
EPS Next 3Y28%
EPS Next 5Y24.77%
Revenue Next Year23.72%
Revenue Next 2Y37.3%
Revenue Next 3Y38.26%
Revenue Next 5Y36.57%

3.3 Evolution

DAWN Yearly Revenue VS EstimatesDAWN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
DAWN Yearly EPS VS EstimatesDAWN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DAWN. In the last year negative earnings were reported.
  • Also next year DAWN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DAWN Price Earnings VS Forward Price EarningsDAWN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DAWN Per share dataDAWN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

  • DAWN's earnings are expected to grow with 28.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.45%
EPS Next 3Y28%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for DAWN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

DAY ONE BIOPHARMACEUTICALS I

NASDAQ:DAWN (2/3/2026, 9:46:09 AM)

11.465

-0.04 (-0.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-02
Earnings (Next)05-01
Inst Owners83.24%
Inst Owner Change0.91%
Ins Owners2.36%
Ins Owner Change0.29%
Market Cap1.18B
Revenue(TTM)133.67M
Net Income(TTM)-151.76M
Analysts82.67
Price Target24.03 (109.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.36%
Min EPS beat(2)20.33%
Max EPS beat(2)36.38%
EPS beat(4)3
Avg EPS beat(4)1.46%
Min EPS beat(4)-73.33%
Max EPS beat(4)36.38%
EPS beat(8)5
Avg EPS beat(8)12.11%
EPS beat(12)9
Avg EPS beat(12)9.7%
EPS beat(16)11
Avg EPS beat(16)4.84%
Revenue beat(2)1
Avg Revenue beat(2)-1.85%
Min Revenue beat(2)-5.83%
Max Revenue beat(2)2.13%
Revenue beat(4)2
Avg Revenue beat(4)-0.24%
Min Revenue beat(4)-5.83%
Max Revenue beat(4)3.01%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.87%
PT rev (3m)1.31%
EPS NQ rev (1m)10.9%
EPS NQ rev (3m)37.95%
EPS NY rev (1m)1.37%
EPS NY rev (3m)17.89%
Revenue NQ rev (1m)5.72%
Revenue NQ rev (3m)10.04%
Revenue NY rev (1m)2.05%
Revenue NY rev (3m)4.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.81
P/FCF N/A
P/OCF N/A
P/B 2.61
P/tB 2.72
EV/EBITDA N/A
EPS(TTM)-1.47
EYN/A
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS1.3
BVpS4.39
TBVpS4.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.54%
ROE -33.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.44%
FCFM N/A
ROA(3y)-35.78%
ROA(5y)-50.98%
ROE(3y)-38.78%
ROE(5y)-56.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 156.44%
Cap/Sales 3.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.68
Quick Ratio 8.55
Altman-Z 9.73
F-Score3
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)635.28%
Cap/Depr(5y)471.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.65%
EPS Next Y42.41%
EPS Next 2Y28.45%
EPS Next 3Y28%
EPS Next 5Y24.77%
Revenue 1Y (TTM)31.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%98.28%
Revenue Next Year23.72%
Revenue Next 2Y37.3%
Revenue Next 3Y38.26%
Revenue Next 5Y36.57%
EBIT growth 1Y21.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year39.85%
EBIT Next 3Y21.73%
EBIT Next 5YN/A
FCF growth 1Y11.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.04%
OCF growth 3YN/A
OCF growth 5YN/A

DAY ONE BIOPHARMACEUTICALS I / DAWN FAQ

Can you provide the ChartMill fundamental rating for DAY ONE BIOPHARMACEUTICALS I?

ChartMill assigns a fundamental rating of 4 / 10 to DAWN.


What is the valuation status for DAWN stock?

ChartMill assigns a valuation rating of 1 / 10 to DAY ONE BIOPHARMACEUTICALS I (DAWN). This can be considered as Overvalued.


What is the profitability of DAWN stock?

DAY ONE BIOPHARMACEUTICALS I (DAWN) has a profitability rating of 2 / 10.


How financially healthy is DAY ONE BIOPHARMACEUTICALS I?

The financial health rating of DAY ONE BIOPHARMACEUTICALS I (DAWN) is 8 / 10.